BioPharmSignal logoBioPharmSignal

Biotech News

BioCryst Reports Third Quarter 2026 Financial Results

BioCryst Pharmaceuticals (BCRX)BioCryst PharmaceuticalsEarnings

— Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715

Related news

BCRXBioCryst Pharmaceuticals2026-10-21 20:01 EST

BioCryst to Report Third Quarter 2026 Financial Results on November 4

CRISCuris Inc2026-11-05 21:38 EST

Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026

INVAInnoviva2026-11-04 21:05 EST

Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress

EXELExelixis2026-10-29 20:05 EST

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

PTCTPTC Therapeutics, Inc.2026-10-29 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

TARAProtara Therapeutics2026-11-06 13:00 EST

Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update

CAPRCapricor Therapeutics2026-11-03 14:00 EST

Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10

ETONEton Pharmaceuticals2026-10-29 10:50 EST

Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026

RAREUltragenyx Pharmaceutical2026-10-27 20:05 EST

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

EXELExelixis2026-10-15 20:05 EST

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

View all latest news

BioCryst Pharmaceuticals

Rare-Disease Drug Development BioCryst Pharmaceuticals discovers, develops and commercializes small-molecule medicines for rare diseases. Its portfolio combines a marketed hereditary angioedema franchise with clinical programs targeting additional protein-mediated disorders. ORLADEYO Commercial Franchise ORLADEYO is an oral preventive...

Recent company news

BCRXBioCryst Pharmaceuticals2026-11-04 21:01 EST

BioCryst to Present at Upcoming Investor Conferences

BCRXBioCryst Pharmaceuticals2026-11-04 12:00 EST

BioCryst Reports Third Quarter 2026 Financial Results

BCRXBioCryst Pharmaceuticals2026-10-29 11:00 EST

BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

BCRXBioCryst Pharmaceuticals2026-10-21 20:01 EST

BioCryst to Report Third Quarter 2026 Financial Results on November 4

BCRXBioCryst Pharmaceuticals2026-10-21 11:00 EST

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

Stock data

Close
7.63 USD
Market cap
2.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States